Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer

NCT04404361 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT04404361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04404361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer
Lead sponsor
CTI BioPharma
Phase
Phase 2
Overall status
Terminated
Start date
May 22, 2020
Completion date
September 21, 2021
Enrollment
200 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

covid, covid-19, covid19